Evoke Neuroscience
Evoke Neuroscience develops a Class II FDA-cleared EEG/ERP medical device for objective cognitive impairment assessment, sold to primary care physicians and neurologists for in-office brain health evaluation; acquired by Firefly Neuroscience in May 2025.
- Company typePrivate
- Founded2009
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Evoke Neuroscience does
Evoke Neuroscience developed and sold a Class II FDA 510(k)-cleared medical device system — the Evoke System — that performs objective cognitive impairment assessments in a physician's office. The platform combines quantitative EEG (qEEG) and event-related potential (ERP) acquisition hardware with proprietary software that analyzes brain electrical activity against a normative database of 191,000+ EEG/ERP sessions (2 billion+ data points), generating Evoke Reports interpreted by physicians to aid in differential diagnosis of cognitive impairment, including Alzheimer's disease, depression, ADHD, TBI, and PTSD. The company was founded in 2009, commercialized the Evoke System in 2014, and received FDA clearance in 2017.
The business model centers on a one-time hardware/software system sale to healthcare providers (primary care physicians and neurologists), augmented by recurring consumables revenue (EEG caps and electrodes) and procedure-based economics enabled by five established CPT reimbursement codes (96138, 95816, 95930, 96132, and 95816-related). Go-to-market is exclusively direct enterprise field sales to clinicians, with institutional channels layered on for federal and large-system buyers: the Veterans Health Administration Federal Supply Schedule (Contract #36F79718D0348), the Premier Healthcare Alliance Breakthrough Technology GPO agreement (Contract PP-MM-722) covering 4,000+ U.S. health systems and 175,000+ providers, and a USAF SBIR Phase I contract. The company has shipped 400+ systems cumulatively and operates from New York, NY and Jacksonville, NC.
In parallel, Evoke was developing a machine-learning-based AI biomarker for Alzheimer's disease diagnosis in partnership with Pacific Neuroscience Institute, training on its proprietary EEG/ERP dataset and targeting near-100% sensitivity and specificity. In May 2025, Evoke was acquired by Firefly Neuroscience for $6 million to integrate its EEG/ERP data, patent portfolio (12 granted patents), and FDA-cleared system into Firefly's planned foundation model of the human brain; Evoke now operates as a brand within Firefly Neuroscience.
Evoke Neuroscience firmographics
Firmographics- Name
- Evoke Neuroscience
- Legal name
- Evoke Neuroscience, Inc.
- Website
- https://evokeneuroscience.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Evoke Neuroscience develops a Class II FDA-cleared EEG/ERP medical device for objective cognitive impairment assessment, sold to primary care physicians and neurologists for in-office brain health evaluation; acquired by Firefly Neuroscience in May 2025.
- Ownership category
- akta.pro rank
Evoke Neuroscience industry classification
Industry- Product category
- Neurological Diagnostic Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
Keywords
Where Evoke Neuroscience is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Evoke Neuroscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain, Infrastructure
Revenue model
- Hardware and Software System Sales: Evoke is sold as a complete hardware/software system to healthcare providers. Purchase includes hardware (EEG amplifier, caps), software required for cognitive assessments, onboarding training, ongoing clinical education, and free software upgrades. Financing options are available.
- Reimbursable Procedures: The Evoke assessment generates reimbursable procedures. Five CPT codes are established: 96138 (Neuropsychological test administration/scoring by technician), 95816 (EEG recording, including awake and drowsy), 95930 (Visual evoked potential testing), 96132 (Neuropsychological test evaluation by physician).
- Consumables Sales: Sale of consumables including EEG caps and electrodes through bio-medical.com and direct contact with account managers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Complete Evoke System with hardware, software, training, and support |
| Transaction based/ take rate | Pay-as-you-go | Reimbursable assessment procedures via established CPT codes |
Go-to-market motion1 record
Distribution channels6 records
Marketing channels8 records
Evoke Neuroscience product offering
Product offeringCore offering
Evoke Neuroscience sells the FDA 510(k)-cleared Evoke™ System, a Class II medical device combining an EEG amplifier with proprietary software that performs quantitative EEG (qEEG) and event-related potentials (ERP) assessments to aid physicians in the diagnosis of cognitive impairment. The system analyzes results against a proprietary normative database of over 191,000 sessions to produce automated Evoke Reports, and is sold exclusively to healthcare providers (primarily primary care physicians and neurologists) for in-office brain health evaluation. A companion Web Portal allows physicians to download reports, access EDF+ files, and track patient cognitive status over time.
Product overview
Evoke Neuroscience offers The Evoke™ System, a unified hardware/software cognitive assessment platform. The system includes an EEG amplifier and a web portal where physicians access automated Evoke Reports. The device performs quantitative EEG (qEEG) and event-related potential (ERP) assessments, analyzing results against a proprietary normative database of over 191,000 sessions containing 2 billion+ data points to aid in the diagnosis of cognitive impairment.
Differentiator
Problem solved
Functional benefit
Products and services
- The Evoke™ System A Class II medical device combining EEG hardware (amplifier) with proprietary software that acquires, displays, and stores electrical brain activity including EEG and event-related potentials (ERP) to aid physicians in the diagnosis of cognitive impairment. Designed for in-office use by healthcare providers (primary care physicians and neurologists); the assessment takes under an hour and yields automated Evoke Reports interpreted by the physician. Purchase includes hardware, software, onboarding training, ongoing clinical education, and free software upgrades.
- Evoke Web Portal Secure web-based platform where physicians download Evoke Reports, access EDF+ files, and track patient cognitive status over time. Used by existing Evoke System customers for report retrieval and longitudinal cognitive status monitoring.
Quantifiable outcome
- 40% of dementia cases can be prevented or delayed with early detection and intervention
- +3 more outcomes
Companies that use Evoke Neuroscience
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Evoke Neuroscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Evoke Neuroscience partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered secondary, core and minor.
- Thought TechnologysecondaryCo-marketing agreement with Thought Technology, a leading manufacturer of psychophysiological monitoring equipment. Evoke provides initial EEG/ERP assessment while Thought Technology provides biofeedback or neurofeedback training, enabling clinicians to offer comprehensive cognitive impairment detection, diagnosis, and support under the same roof.
- U.S. Air ForcecoreSBIR Phase I contract award from Air Force Research Lab (AFRL) and AFWERX for diagnostic device evaluation. Contract part of USAF Small Business Innovation Research program to provide evoke System for mTBI, PTSD, and cognitive symptom assessment for service members.
- Allied CorpminorLetter of Intent signed with Allied Corp (OTC Pink: ALID) for partnership on analysis and treatment of PTSD patients. Evoke System would be used to assess CNS/ANS function via EEG, ECG, and ERPs to support Allied's clinical trials and differentiate their therapy products.
- Premier Healthcare AlliancecoreBreakthrough Technology agreement with Premier Inc., a healthcare improvement company uniting 4,000+ U.S. health systems and 175,000+ providers. Contract PP-MM-722 enables Premier members to access special pricing on the Evoke System.
- Department of Veterans AffairscoreVeterans Health Administration FSS Contract #36F79718D0348 enables VA hospitals and outpatient clinics to purchase the Evoke System at pre-approved pricing via FSS Contract, GSA Advantage, or GSA eBUY. Evoke has long history supporting military personnel and veterans with cognitive health needs.
- Pacific Neuroscience Institute Brain Health CentercorePartnership with Pacific Neuroscience Institute Brain Health Center (outpatient clinic of Providence Saint John's Health Center in Santa Monica, CA) for AI biomarker development study. IRB approved study using Evoke to measure EEG & ERP biomarkers for 300 patients with cognitive impairment to train machine learning models for Alzheimer's diagnosis.
- Endless Frontier LabssecondaryResearch collaborator for AI biomarker development and brain health technology advancement.
- UCI IrvinesecondaryResearch collaborator in neuroscience and brain health research.
- Society for Brain MappingminorResearch collaborator in brain mapping and cognitive assessment technology.
Scale indicators8 records
Recent moves8 records
Expansion highlights5 records
Evoke Neuroscience competitors and assessment
Company assessmentDirect peers
- Linus Health: Linus Health offers a digital cognitive assessment platform combining tablet-based testing and AI-driven speech/handwriting biomarkers for early detection of cognitive impairment. Comparable to Evoke in serving primary care and neurology for early detection of dementia and MCI.
- Altoida: Altoida is building digital biomarkers for neurodegenerative disease using augmented-reality cognitive tasks on smartphones/tablets. Comparable to Evoke in developing objective, technology-mediated cognitive assessment for early detection and pharmaceutical/research applications.
- Cambridge Cognition: Cambridge Cognition delivers computerized cognitive assessments, including CANTAB battery, for CNS clinical trials and healthcare. Closely comparable to Evoke in cognitive endpoint data offerings and overlap in clinical research and neurology customer segments.
- Cogstate: Cogstate provides computerized cognitive testing for clinical trials, healthcare, and concussion management. Comparable to Evoke in providing objective cognitive assessment tools to clinicians and researchers, with established CPT-reimbursable products in U.S. healthcare.
- BrainCheck: BrainCheck is a digital cognitive assessment platform used by physicians for rapid, in-office detection of cognitive impairment and concussion. Comparable to Evoke in serving primary care and specialty clinicians with cognitive impairment screening tools, though using tablet-based assessments rather than qEEG/ERP.
- BrainScope: BrainScope is an EEG-based medical device company focused on traumatic brain injury (TBI) and concussion assessment, with strong U.S. military and VA channel presence. Directly comparable to Evoke on EEG acquisition, FDA-cleared triage diagnostics, and DoD/VA go-to-market.
- Cumulus Neuroscience: Cumulus Neuroscience is developing a multi-modal EEG-based platform for CNS clinical trial endpoints and clinical biomarker assessment. Highly comparable to Evoke's qEEG/ERP biomarker approach and similar target customers in neurology trials and brain health assessment.
Broad incumbents
- Compumedics Limited: Compumedics is an Australian-headquartered manufacturer of clinical EEG, sleep, and brain research equipment. Comparable to Evoke in supplying EEG acquisition systems to clinical and research customers, though at broader scale across multiple neurodiagnostic categories.
- Natus Neuro / Neuroscan: Natus Neuro (including the Neuroscan product line) is a broad incumbent manufacturer of clinical EEG hardware and software used across neurology, sleep, and research. Overlaps with Evoke in clinical EEG acquisition and analysis, though Natus serves a wider portfolio across neurodiagnostics.
Others
- ANT Neuro: ANT Neuro is a Dutch manufacturer of EEG caps, electrodes, and high-density EEG systems. It is an enabling hardware provider to Evoke (whose consumables/partners list includes ANT Neuro caps) and an adjacent ecosystem player rather than a direct competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Evoke Neuroscience social profiles
Digital presenceEvoke Neuroscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Evoke Neuroscience leadership team
Management profileNumber of profiles
Profiles4 records
Evoke Neuroscience funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Evoke Neuroscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Evoke Neuroscience
What does Evoke Neuroscience do?
Evoke Neuroscience sells the FDA 510(k)-cleared Evoke™ System, a Class II medical device combining an EEG amplifier with proprietary software that performs quantitative EEG (qEEG) and event-related potentials (ERP) assessments to aid physicians in the diagnosis of cognitive impairment. The system analyzes results against a proprietary normative database of over 191,000 sessions to produce automated Evoke Reports, and is sold exclusively to healthcare providers (primarily primary care physicians and neurologists) for in-office brain health evaluation. A companion Web Portal allows physicians to download reports, access EDF+ files, and track patient cognitive status over time.
Is Evoke Neuroscience a public or private company?
Evoke Neuroscience is a private company. It is classified as corporate owned and is currently acquired.
When was Evoke Neuroscience founded?
Evoke Neuroscience was founded in 2009. It employs 11 to 50 people.
Where is Evoke Neuroscience based?
Evoke Neuroscience is headquartered in New York, United States, in the North America region.
How does Evoke Neuroscience make money?
Three revenue lines are on record. Hardware and Software System Sales are the primary driver. The others are reimbursable Procedures and consumables Sales.
Who are Evoke Neuroscience's main competitors?
Direct peers on record are Linus Health, Altoida, Cambridge Cognition, Cogstate, BrainCheck, BrainScope and Cumulus Neuroscience. Broad incumbents are Compumedics Limited and Natus Neuro / Neuroscan. ANT Neuro is listed as an others.
Does Evoke Neuroscience have an API?
No public API is recorded for Evoke Neuroscience.
What industry is Evoke Neuroscience in?
Evoke Neuroscience's product category is Neurological Diagnostic Devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.